Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Feet First · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Feet First | EXPERIMENTAL | Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks. |
| Control | NO_INTERVENTION | Usual care |
| Name | Type | Description |
|---|---|---|
| Feet First | BEHAVIORAL | Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks. |
Inclusion Criteria: * Diagnosed type 1 or 2 diabetes mellitus * Age 50 years or older * Absent 5.07 Semmes Weinstein monofilament sensation to \> 1 point on both feet * Residence within 50 miles of Columbia, MO * Functioning telephone service * Not currently participating in 20 or more minutes of m...
Feet First is an investigational intervention being studied for use in diabetes mellitus, specifically in people with diabetes mellitus and insensate feet. It is being evaluated as a way to promote physical activity in this patient population. The drug is currently in Phase 1 clinical development.
Feet First is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical research on this investigational intervention for patients with diabetes mellitus and peripheral neuropathies.
Feet First is in Phase 1 clinical development. It is an investigational intervention and has not been approved by regulatory authorities. One clinical trial for Feet First has been completed, and the intervention remains under study for its potential use in diabetes mellitus.
Feet First has one completed clinical trial registered under NCT00286598, titled "Feet First: Promoting Physical Activity Among People With Diabetes Mellitus and Insensate Feet." This Phase 1 study enrolled 79 participants in the United States, with a minimum age of 50 years, and included both sexes.
No alternative names for Feet First have been identified. The intervention is known by the name Feet First in clinical research, and no other drug names have been associated with it in the available information.